Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

ERIS's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.443369
debtToEquity 75.737000
earningsGrowth 0.416000
revenueGrowth 0.078000
grossMargins 0.748830
operatingMargins 0.267250
trailingEps 28.310000
forwardEps 41.650000

Eris Lifesciences Limited's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
ERIS's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
ERIS's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that ERIS's financial performance will improve in the current financial year.

Price projections:

Price projections for ERIS
Price projections for ERIS

Eris Lifesciences Limited's current price does not reveal any distinct risks or opportunities compared to its projections. This neutral assessment suggests stability, where investors might choose to retain their current positions until future developments warrant a reassessment.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts are favoring ERIS with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider ERIS as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.